e-learning
resources
London 2016
Monday, 05.09.2016
Microbiological issues and translational research in respiratory infections
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Development of an antibody therapy for the treatment of pneumonia
Jenny Herbert (London, United Kingdom), Jenny Herbert, Timothy Mitchell
Source:
International Congress 2016 – Microbiological issues and translational research in respiratory infections
Session:
Microbiological issues and translational research in respiratory infections
Session type:
Thematic Poster
Number:
2623
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Jenny Herbert (London, United Kingdom), Jenny Herbert, Timothy Mitchell. Development of an antibody therapy for the treatment of pneumonia. Eur Respir J 2016; 48: Suppl. 60, 2623
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Related content which might interest you:
Surfactant-enforced treatment of
pseudomonas
-induced pneumonia
Source: Annual Congress 2013 –Novel drugs and biomarkers in respiratory medicine
Year: 2013
Modification of empirical antibiotic therapy in community acquired pneumonia
Source: International Congress 2014 – Different interesting issues in respiratory infections: 2
Year: 2014
Dynamic of adherence to guidelines for antibiotic therapy of community-aquired pneumonia (CAP)
Source: Annual Congress 2013 –Antibiotics, resistance and vaccines
Year: 2013
Factors affecting treatment success in community acquired pneumonia (CAP)
Source: Annual Congress 2013 –Pneumonia and sepsis
Year: 2013
Empirical treatment of community-acquired pneumonia after outpatient beta-lactam therapy
Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment
Year: 2016
Benefits of co-administration of macrolides and glucocorticosteroids in the treatment of severe community acquired pneumonia
Source: International Congress 2016 – Community-acquired pneumonia: update on prognostic factors and therapeutic strategies
Year: 2016
Predictors of treatment failure in patients with bacteremic pneumococcal community-acquired pneumonia
Source: Annual Congress 2013 –Pneumonia and sepsis
Year: 2013
Colistin therapy for nosocomial pneumonia and nephrotoxicity
Source: Annual Congress 2013 –Antibiotics, resistance and vaccines
Year: 2013
The impact of mixed etiology in community acquired pneumonia (CAP)
Source: International Congress 2014 – Respiratory infections: inflammation and treatment
Year: 2014
Impact of bacterial coinfection on clinical outcomes in pneumococcal pneumonia
Source: International Congress 2015 – Pneumonia: determinants of clinical outcomes and potential strategies to improve its management
Year: 2015
Drug-resistant pathogens prediction scores in CAP, HCAP and immunocompromised
Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options
Year: 2014
Shortening duration of antibiotic therapy according to clinical stability in patients with community-acquired pneumonia (CAP)
Source: International Congress 2014 – Respiratory infections: inflammation and treatment
Year: 2014
Breakthrough invasive pulmonary aspergillosis (IPA) in patients receiving posaconazole prophylaxis (PPxis)
Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options
Year: 2014
Immunoglobulin levels and severity of community-acquired pneumonia (CAP)
Source: International Congress 2014 – Pathogenesis and mechanisms of respiratory infections
Year: 2014
Bacteremia in non-HIV community acquired pneumonia
Source: Annual Congress 2013 –Pneumonia and sepsis
Year: 2013
Community adquired
legionella pneumophila
pneumonia in elderly patients
Source: International Congress 2014 – Epidemiology, scores and outcomes of respiratory infections
Year: 2014
Can the broad-spectrum antibiotics improve the prognoses of high-risk nursing- and healthcare-associated pneumonia?
Source: International Congress 2014 – Epidemiology, scores and outcomes of respiratory infections
Year: 2014
Modern etiology of severe community-acquired pneumonia
Source: International Congress 2016 – Community-acquired pneumonia: risk classes and management issues
Year: 2016
Common organisms causing community acquired pneumonia
Source: Annual Congress 2013 –Bacterial, fungal and mycobacterial infections
Year: 2013
Comparative evaluation of timing of antibiotic intravenous-to-oral switch in pneumonia
Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept